Cardium Therapeutics, Inc.
(NYSE Mkt: CXM)

Taxus Cardium Pharmaceuticals Group Inc, formerly Cardium Therapeutics, Inc., is a development-stage company. It�s business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. With additional products and distribution channels, the Company plans to develop MedPodium into a portfolio of science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics intended to promote and manage personal health. On December 31, 2011, the Company acquires 15% ownership interest in SourceOne Global Partners, LLC. In October 2012, its MedPodium operating unit acquired the assets, business and product portfolio of To Go Brands.

7.810 s

-0.085 (-1.08%)
Range 7.790 - 7.940   (1.93%)
Open 7.940
Previous Close 7.895
Bid Price 3.800
Bid Volume 47,100
Ask Price 3.810
Ask Volume 76,900
Volume 204,227
Value -
Remark s
Delayed prices. Updated at 05 Dec 2025 23:04.
Data powered by
View All Events

About Cardium Therapeutics, Inc.

Taxus Cardium Pharmaceuticals Group Inc, formerly Cardium Therapeutics, Inc., is a development-stage company. It�s business is focused on the acquisition and strategic development of product opportunities or businesses having the potential to address unmet medical needs. With additional products and distribution channels, the Company plans to develop MedPodium into a portfolio of science-based, easy to use medicinals, neurologics, metabolics, nutraceuticals and aesthetics intended to promote and manage personal health. On December 31, 2011, the Company acquires 15% ownership interest in SourceOne Global Partners, LLC. In October 2012, its MedPodium operating unit acquired the assets, business and product portfolio of To Go Brands.

Please login to view stock data and analysis